Pierre Fabre SAS in US$31m licence deal with Kinnate Biopharma Inc
With the US$31m agreement Pierre Fabre licences the global rights to exarafenib and other pan-RAF program assets from Kinnate...
Spexis sells antibiotics programme to Basilea
Spexis AG (Alschwil) has entered into an asset purchase agreement with Basilea Pharmaceutica Ltd. Under the agreement Basilea will acquire a...
German companies to revolutionise lab plastics market
Plastic consumables used in pharmaceutical and biotechnological research must meet high quality standards. A German start-up has now launched the...
miRNA specialist Resalis Therapeutics Srl raises €10m in Series A financing
Existing investors including Claris Ventures and angel investors participated in the financing The proceeds will be used to initiate and complete the...
Scientists create non-digestible aptamer
The synthetic TNA nucleic acid analogues created by a biochemists at University of Cologne hrepresent a so called threofuranosyl nucleic acid...
Researcher find potential target for atherosclerosis
Researchers have found a new way to reverse atherosclerotic plaque formation at the early stages. In Nature Cardiovascular Research, Alma...
Alfasigma SpA signs €170m deal with Galapagos NV
With the transaction that is expected to close in Q1/2024, Alfasigma will strengthen its pipeline, add a new Phase III programme to...